APA (7th ed.) Citation

Kedor, C., Listing, J., Zernicke, J., Weiß, A., Behrens, F., Blank, N., . . . Feist, E. (2020). Canakinumab for treatment of adult-onset still’s disease to achieve reduction of arthritic manifestation (CONSIDER): Phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Annals of the rheumatic diseases, 79(8), . https://doi.org/10.1136/annrheumdis-2020-217155

Chicago Style (17th ed.) Citation

Kedor, Claudia, et al. "Canakinumab for Treatment of Adult-onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): Phase II, Randomised, Double-blind, Placebo-controlled, Multicentre, Investigator-initiated Trial." Annals of the Rheumatic Diseases 79, no. 8 (2020). https://doi.org/10.1136/annrheumdis-2020-217155.

MLA (9th ed.) Citation

Kedor, Claudia, et al. "Canakinumab for Treatment of Adult-onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): Phase II, Randomised, Double-blind, Placebo-controlled, Multicentre, Investigator-initiated Trial." Annals of the Rheumatic Diseases, vol. 79, no. 8, 2020, https://doi.org/10.1136/annrheumdis-2020-217155.